Health Economics›Non-small cell lung cancer›Advanced or metastatic disease second-line

Advanced or metastatic disease second-line

Non-small cell lung cancer · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 90 983	28d	4.3 mo	—	5	R 454 914 PFS proxy	1
Cabozantinib and Erlotinib Variant #01	—	R 74 562	28d	4.7 mo	—	6	R 447 373 PFS proxy	1
Docetaxel and Ramucirumab Variant #01	—	R 61 872	21d	—	10.5 mo	—	—	1
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	—	9.5 mo	—	—	1
Gefitinib monotherapy Variant #01	—	R 8 556	28d	3.4 mo	7.6 mo	4	R 34 222 PFS proxy	6
Docetaxel and Vandetanib Variant #01 Partial	—	R 2 069	21d	4.0 mo	—	6	R 12 416 PFS proxy	1
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	3.2 mo	9.8 mo	4	R 973 PFS proxy	39
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	2.9 mo	8.3 mo	5	R 347 PFS proxy	9
Carboplatin and Pemetrexed N/A - secondary systemic drug	—	R 52	21d	3.5 mo	—	6	R 312 PFS proxy	1
Vinflunine monotherapy Variant #01 Partial	—	—	21d	2.3 mo	—	4	—	1

10 of 10 regimens shown